Kurzfassung

An exploratory, open-label, multicenter study to evaluate the safety and efficacy of a twodose regimen of ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment), in patients with a hematologic
malignancy, who received a CD34-selected hematopoietic stem cell transplantation from a haploidentical donor.